Upcoming · By Invitation

International Translational Oncology Exchange

Boston · May 13, 202614:00 – 16:00 ET
Learn more →
←Back to Expert Scholars
research / researchregulatory T cells in cancer

Hiroyoshi Nishikawa

西川博嘉

MD, PhD

🏢National Cancer Center Research Institute, Japan(日本国立癌症研究中心研究院)🌐Japan

Division Head, Cancer Immunology癌症免疫学部门主任

65
h-index
2
Key Papers
2
Awards
2
Key Contributions

👥Biography 个人简介

Hiroyoshi Nishikawa is a Japanese tumor immunologist who has made significant contributions to understanding how regulatory T cells (Tregs) in the tumor microenvironment suppress anti-tumor immunity and promote immune evasion. His laboratory characterized that Foxp3+ Tregs are enriched in tumor-draining lymph nodes and tumor sites, and that Treg depletion can restore anti-tumor immunity. Nishikawa demonstrated that CCR4 is highly expressed on tumor-infiltrating Tregs and that anti-CCR4 antibody (mogamulizumab) depletes intratumoral Tregs, providing the rationale for combining anti-CCR4 with PD-1 blockade. This work contributed to clinical development of mogamulizumab combinations.

Share:

🧪Research Fields 研究领域

regulatory T cells in cancer调节性T细胞在癌症中
Foxp3 Treg biologyFoxp3 Treg生物学
Treg depletion therapyTreg耗竭治疗
tumor immune evasion Japan日本肿瘤免疫逃逸
CCR4 Treg targetingCCR4 Treg靶向

🎓Key Contributions 主要贡献

Treg Tumor Immune Suppression

Characterized Foxp3+ Treg enrichment in human tumor microenvironments and demonstrated through depletion models that intratumoral Tregs are a major mechanism of immunosuppression limiting anti-tumor immune responses.

CCR4 Treg Targeting

Demonstrated CCR4 expression on intratumoral Tregs and provided preclinical evidence that mogamulizumab depletes this immunosuppressive population, supporting clinical trials combining anti-CCR4 with PD-1 checkpoint inhibitors.

Representative Works 代表性著作

[1]

Human CD4+ Foxp3+ Regulatory T Cells in Tumor Microenvironment

Journal of Experimental Medicine (2008)

Characterization of Tregs in human tumor microenvironments.

[2]

CCR4+ Regulatory T Cells as a Therapeutic Target

Nature Medicine (2020)

Anti-CCR4 Treg depletion rationale for cancer immunotherapy.

🏆Awards & Recognition 奖项与荣誉

🏆Japanese Society for Immunology Asahi Prize
🏆Japan Cancer Research Foundation Award

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Faisal Mahmood

Brigham and Women's Hospital; Harvard Medical School

Computational Pathology — Deep Learning for Whole-Slide Image Analysis and Tumor Microenvironment CharacterizationFoundation Models for Pathology — CONCH and TITAN Vision-Language Models for Oncology

Kun-Hsing Yu

Harvard Medical School; Brigham and Women's Hospital

Multimodal Oncology AI — Integrating Pathology Images, Genomics, Proteomics, and Clinical RecordsAI Pathology-Genomics Integration — Predicting Molecular Alterations from Histomorphology

Ziad Obermeyer

University of California, Berkeley; UC San Francisco

Algorithmic Bias in Healthcare AI — Racial Disparities in Predictive Risk ScoresPredictive Models for Cancer and Critical Illness — Machine Learning in Clinical Practice

Andrew H. Beck

PathAI; Harvard Medical School (formerly)

PathAI — Founding and Scientific Direction of AI-Powered Pathology PlatformDeep Learning for Pathology Biomarker Discovery — TILs, Fibrosis, and Tumor Architecture

关注 西川博嘉 的研究动态

Follow Hiroyoshi Nishikawa's research updates

留下邮箱，当我们发布与 Hiroyoshi Nishikawa（National Cancer Center Research Institute, Japan）相关的新研究或访谈时，我们会通知你。

我们不会泄露你的信息，也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All ExpertsRead Research Insights